Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.890
+0.160 (9.25%)
At close: May 19, 2026, 4:00 PM EDT
1.890
0.00 (0.00%)
After-hours: May 19, 2026, 7:11 PM EDT
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$39,230
Profits / Employee
-$806,876
Market Cap
220.30M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -20 | -11.05% |
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Sep 30, 2022 | 545 | 155 | 39.74% |
| Jun 30, 2022 | 542 | 186 | 52.25% |
| Mar 31, 2022 | 511 | 197 | 62.74% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Sep 30, 2021 | 390 | 111 | 39.78% |
| Jun 30, 2021 | 356 | - | - |
| Mar 31, 2021 | 314 | 136 | 76.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| MediWound | 121 |
| Arcturus Therapeutics Holdings | 111 |
| Nkarta | 108 |
| Caribou Biosciences | 97 |
| Keros Therapeutics | 78 |
| Cartesian Therapeutics | 75 |
| Milestone Pharmaceuticals | 38 |
FATE News
- 4 hours ago - Fate Therapeutics assumed with a Buy at Jefferies - TheFly
- 6 days ago - Fate Therapeutics reports Q1 EPS (26c), consensus (28c) - TheFly
- 6 days ago - Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 6 days ago - Fate Therapeutics Earnings release: Q1 2026 - Filings
- 6 days ago - Fate Therapeutics Quarterly report: Q1 2026 - Filings
- 8 days ago - Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting - GlobeNewsWire
- 14 days ago - Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - GlobeNewsWire
- 15 days ago - Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - GlobeNewsWire